Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | BTN3A1 | O00481 | 6/20 | 0.40 |
| ▸ | OGG1 | O15527 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723907 | 1.00 | HTT (0.41) | HTTALDH1A1KDM4EHSD17B10BTN3A1 | |
| SCHEMBL1743835 | 1.00 | HTT (0.41) | HTTALDH1A1KDM4EHSD17B10BTN3A1 | |
| SCHEMBL10208172 | 1.00 | HTT (0.41) | HTTALDH1A1KDM4EHSD17B10BTN3A1 | |
| SCHEMBL10208250 | 0.89 | CASP3 (0.40) | HTTALDH1A1KDM4EHSD17B10BTN3A1 | |
| SCHEMBL723663 | 0.89 | BTN3A1 (0.39) | HTTALDH1A1KDM4EHSD17B10BTN3A1 | |
| SCHEMBL723664 | 0.89 | BTN3A1 (0.39) | HTTALDH1A1KDM4EHSD17B10BTN3A1 | |
| SCHEMBL15582401 | 0.89 | HTT (0.41) | HTTALDH1A1KDM4EHSD17B10BTN3A1 | |
| SCHEMBL18067177 | 0.89 | HTT (0.41) | HTTALDH1A1KDM4EHSD17B10BTN3A1 | |
| SCHEMBL18067133 | 0.89 | HTT (0.41) | HTTALDH1A1KDM4EHSD17B10BTN3A1 | |
| SCHEMBL16865720 | 0.89 | HTT (0.41) | HTTALDH1A1KDM4EHSD17B10BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20220033433-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-02-03 | — | — | US | disclosed |
| US-11040997-B2 | Process for preparing nucleoside prodrugs | NuCana plc (GB) | 2021-06-22 | — | — | US | disclosed |
| EP-3235824-B1 | MIXTURE OF RP/SP GEMCITABINE-[PHENYL-(BENZYLOXY-L-ALANINYL)]-PHOSPHATE | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-03-27 | — | — | EP | disclosed |
| US-10005810-B2 | Process for preparing nucleoside prodrugs | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-10005810-B2 | Process for preparing nucleoside prodrugs | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-9862743-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| WO-2014076490-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014008236-A1 | PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013070887-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013066991-A1 | CRYSTALLINE SOLVATES OF NUCLEOSIDE PHOSPHOROAMIDATES, THEIR STEREOSELECTIVE PREPARATION, NOVEL INTERMEDIATES THEREOF, AND THEIR USE IN THE TREATMENT OF VIRAL DISEASE | INHIBITEX, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | HTT 2179/4885ALDH1A1 1431/4885KDM4E 3890/4885 |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | HTT 2589/4885ALDH1A1 4139/4885KDM4E 4140/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | HTT 2179/4885ALDH1A1 1431/4885KDM4E 3890/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | HTT 2145/4885ALDH1A1 1153/4885KDM4E 3122/4885 |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | HTT 1598/4885ALDH1A1 2525/4885KDM4E 3667/4885 |
| US-11040997-B2 | Process for preparing nucleoside prodrugs | PNP, TYMP, SLC29A1 | HTT 4234/4885ALDH1A1 2544/4885KDM4E 2416/4885 |
| US-20220033433-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | PNP, MTAP, TYMP | HTT 3772/4885ALDH1A1 2613/4885KDM4E 2378/4885 |
| US-10005810-B2 | Process for preparing nucleoside prodrugs | PNP, TYMP, SLC29A1 | HTT 4003/4885ALDH1A1 2729/4885KDM4E 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.